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Metabolic proﬁlingMetabolomics, a high-throughput global metabolite analysis, is a burgeoning ﬁeld, and in recent times has
shown substantial evidence to support its emerging role in cancer diagnosis, cancer recurrence, and
prognosis, as well as its impact in identifying novel cancer biomarkers and developing cancer therapeutics.
Newly evolving advances in disease diagnostics and therapy will further facilitate future growth in the ﬁeld
of metabolomics, especially in cancer, where there is a dire need for sensitive and more affordable
diagnostic tools and an urgency to develop effective therapies and identify reliable biomarkers to predict
accurately the response to a therapy. Here, we review the application of metabolomics in cancer and
mitochondrial studies and its role in enabling the understanding of altered metabolism and malignant
transformation during cancer growth andmetastasis. The recent developments in the area of metabolic ﬂux
analysis may help to close the gap between clinical metabolomics research and the development of cancer
metabolome. In the era of personalized medicine with more and more patient speciﬁc targeted therapies
being used, we need reliable, dynamic, faster, and yet sensitive biomarkers both to track the disease and to
develop and evolve therapies during the course of treatment. Recent advances in metabolomics along with
the novel strategies to analyze, understand, and construct the metabolic pathways opens this window of
opportunity in a very cost-effective manner. This article is part of a Special Issue entitled: Bioenergetics
of Cancer.ergetics of Cancer.
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Metabolomics, the term introduced by Fiehn et al. [1,2], is a
technique involved in the global detection of several small molecule
metabolites and identiﬁcation of metabolic preprogramming i.e.
changes occurring in metabolic pathways and phenotypes. Metabo-
lomics also involves characterization of metabolic phenotyping, i.e.
classiﬁcation of time varying alterations in metabolism, and
discovering metabolite imbalances or stress induced loss of
homeostasis. Hence, metabolomics can be deﬁned as the quantiﬁ-
cation and analysis of dynamic changes in metabolites under either
certain culture or biological conditions or in response to the micro-
environment and/or agonists/antagonists. In deﬁning metabolo-
mics, it will be prudent to go through the few other terminologies,
which provide analogous or metabolic phenotypic information.
Metabolomics refers to the detection of all of the metabolites in
samples, whereas “Metabonomics” refers to the changes in metab-olism due to altered environment. Altered environments include
changes in diet, changes in drug consumption and development of
diseases. On the other hand, “metabolite footprinting” is a high-
throughput technique for analysis of metabolites that are secreted or
consumed by cells or tissues in extracellular media, and has been
very effective in analyzing microbial metabolism [3]. Metabolite
footprinting, or exometabolome, has various advantages over
“metabolic ﬁngerprinting,” which is a technique for analyzing
intracellular metabolites that relies more on classifying the samples
in different states. The other commonly used technique, “metabolite
proﬁling,” involves characterizing and measuring metabolites. The
dynamic analysis of metabolic systems can be achieved by perturb-
ing the extracellular/tissue environment and performing metabolite
proﬁling over time series and further estimating metabolite ﬂuxes
(Fig. 1).
Although metabolomics has been in existence for several
decades it has not received much attention in clinical research
compared to its sister omic sciences such as transcriptomics,
genomics and proteomics. This is quite surprising given that
metabolomics has been used for at least past 2 decades to decipher
congenital disorders and inborn genetic errors of metabolism.
However, technological advances in both instrumentation including
mass spectrometry (MS), nuclear magnetic resonance (NMR), gas
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software has led to a recent surge in utilization of metabolomics in
cancer diagnostics, prognosis, and therapeutics and in various other
metabolic diseases. Indeed, while it is known that transcriptomics
and genomics have played a major role in understanding and
solving cancer and other diseases, it is a little known fact that
metabolic changes are more sensitive to environmental perturba-
tions and can easily track genetics as well as stress, diet and
environment related physiological changes. As compared to tran-
scriptomics and proteomics, metabolomics holds promise because
of several reasons: (a) phenotypic changes are reﬂected as
downstream adaptations and alterations in metabolome, thus
perturbations are ampliﬁed when they are translated to metabo-
lome as compared to transcriptome and genome, thus making
metabolomics a highly sensitive technique in comparison with
transcriptomics and genomics; (b) proﬁling of metabolic bio-
markers is much cheaper and sample preparation is simpler; (c) it
is easier to compare data over several conditions and biochemical
derangements; (d) it allows for easy transfer of analysis between
organisms [3].
As other -omics ﬁelds, metabolomics started within the century
and has advanced signiﬁcantly (Table 1). Metabolomics grew when
news of a doctored report that NMR can detect cancer was published
in the 1980s [4]. Interestingly, at present, metabolomics is widely
being researched in cancer, and it has shown that cancer and normal
cells produce altered metabolic proﬁles that can aid in disease
detection, predicted response to therapy, and development of new
therapies (Table 2). Metabolomics can be categorized as either one
of two main classes: global or speciﬁc. Global metabolomics surveys
changes in the quantities of a large number of metabolites underFig. 1. Schematic of mass spectrometry- (MS) and nuclear magnetic resonance- (NMR) based
are amenable for use in current metabolomics techniques. GC-MS technique derives its
deconvoluted and then analyzed using supervised and unsupervised chemometrics-based
fashion. However, enzymatic activity and UPLC is also suitable for these samples because ocertain conditions to ﬁnd interesting metabolic trends, whereas
speciﬁc metabolomics surveys changes in a smaller number of
metabolites that are hypothesized to be altered under certain
conditions. Metabolomics involves speciﬁc methodical steps. It
involves 1) extraction of metabolites from tissues or cells, 2)
methods to quantify the metabolite changes observed due to altered
cell culture or tissue conditions, and 3) methods of data analysis.
Both global and speciﬁc metabolomics involve similar metabolite
extraction methods for particular analysis used and similar tech-
niques to analyze the data. The two most used methods for
quantifying data are NMR or gas chromatography paired with
mass spectrometry (GC/MS). Additionally, a variety of computer
programs have been used to analyze data, which will be later
discussed.
Signiﬁcant advances in the ﬁeld of metabolomics have been
made, especially from the disease standpoint. To give an example, it
has been widely used in the study of cardiovascular disease and
arthritis [5,6]. The interest in the use of metabolomics in the study
of cancer began when Otto Warburg proposed the Warburg effect—
that cancer cells switch from producing most of their energy in the
form of adenosine triphosphate (ATP) through OXPHOS to produc-
ing most of their energy through glycolysis. This observation
sparked the interest in studying the metabolomics in many types
of cancer, including colon [7,8], ovarian [9,10], hepatocellular
carcinoma [11], and breast cancers [12]. Metabolomics has been
used to study biomarkers for these cancers in order to aid in early
detection of disease, especially in cancers where early detection and
screening is difﬁcult but results in better prognosis. For example,
kidney cancer is one disease that is not normally detected at an
early stage because of screening difﬁculty. Kim et al. showed thatmetabolic strategies for cancer diagnostics. Bioﬂuids such as urine, saliva, tissue, blood
high resolution because of derivatization technique. The data obtained are further
classiﬁcation techniques. The extracellular media from cells are analyzed in a similar
f reduced complexity.
Table 1
Usage of metabolomics techniques in basic science.
Proteins and pathways Techniques Ref.
Metabolism of alcohol through tryptophan build-up due to PPAR-a deletion Mass Spectrometry [92]
Pathways responsible for insulin deﬁciency H1 NMR, liquid chromatography-tandem mass spectrometry [86]
Understanding chemotherapy drug toxicity pathways Ultra-performance chromatography-linked electrospray ionization quadrupole
time-of-ﬂight mass spectroscopy
[93]
Understanding of pathways involved in action of chemotherapy drugs bezaﬁbrate
(BEZ) and medrosxyprogesterone acetate (MPA)
H1-NMR [94]
Understand DNA Damage Repair Pathway involved in Cancer Tandem mass spectrometry [95]
Identify metabolites and pathways whose levels are dependent on long-chain
fatty acid combustion rate, which is associated with insulin resistance
Gas Chromatography/TOF-Mass Spectrometry [42]
Nutrient Gene Interactions Isotope tracer based mass spectrometry [96]
Metabolic adaptation during hypoxia in drosophila ﬂies 1 H NMR spectroscopy [97]
Eicosanoid metabolism and lipidomics ﬂux analysis Enzymatic activity [98]
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chromatography and mass spectrometry (HILIC-MS) can be used to
detect biomarkers for kidney cancer [13]. Gao et al. also used
metabolic proﬁling of human serum in order to determine bio-
markers alterations speciﬁc to renal cell carcinoma [14]. Apart from
kidney cancer, ovarian cancer metabolomics is also being widely
studied. Odunsi et al. have used H-NMR on serum in order to create
a metabolic ﬁngerprint for ovarian cancer as compared to normal
postmenopausal women and were able to see signiﬁcant metabolic
differences using a variety of analysis techniques [15]. Metabolo-
mics of prostate cancer is also being studied for a screening
sensitivity and speciﬁcity that is higher than the gold standard
sensitivity and speciﬁcity using serum prostate speciﬁc antigen
(PSA) alone as a measure. Teahan et al. have conducted metabo-
nomics (NMR metabolic proﬁling) on a non-tumorigenic prostate
epithelial cell line and other tumorigenic prostate cell lines,
analyzed alterations in intracellular and extracellular metabolites.
Results showed that phosphatidyl choline amounts increased in the
transformed cells, whereas branched amino acid amounts decreased
in transformed cells [16].
Metabolomics can also be useful from the therapeutic perspec-
tive, since biomarkers can also be readily identiﬁed that can
distinguish people who will respond to certain therapies from
those that do not respond to therapy. Metabolomics has also
proven useful in determining the effect of drugs on cancer. It
was shown through metabolomic analysis that bezaﬁbrate and
medroxyprogesterone when administered together act to increase
reactive oxygen species in Acute Myeloid Leukemia (AML) cellsTable 2
Usage of metabolomics techniques in clinical cancer research.
Purpose T
Metabolic analysis of biomarkers in renal cell carcinoma H
Detection epithelial ovarian cancer in tissue specimens H
Detection of oesophageal cancer G
Create hepatocellular carcinoma metabolic proﬁles to use for potential
early diagnosis
N
Create metabolic proﬁle for potential early diagnosis of prostate cancer N
Create metabolic proﬁle for early oral cancer detection H
Investigate potential biomarkers for hepatocellular carcinoma G
Molecular signature for kidney cancer detection H
Use metabolic signatures to differentiate between liver cancer and hepatitis
and hepatocirrhosis
H
Use Metabolomics for detecting drug resistance in cancer N
Metabolic analysis of invasive and borderline ovarian Cancers G
Altered metabolism in human lung cancer patients in situ Ntherefore uncovering the mechanism behind cell death due to the
drugs [17]. Furthermore, metabolomics can also be applied in
evaluating the efﬁcacy of radiotherapy. For example, Lyng et al.
have employed a special type of NMR in order to determine the
metabolic proﬁle associated with apoptosis of cervical carcinoma
cells in response to radiotherapy [18]. All these studies show that
there are a number of signiﬁcant metabolomic studies underway
which could potentially yield much needed outcomes, not only
determine the effect of existing therapies but also could create
new therapies.
Due to the versatility of its use in disease diagnostics and therapy,
it can be predicted that research in metabolomics will grow in the
future, especially in the cancer ﬁeld where there is a great need for
more sensitive and speciﬁc cost-effective diagnostic tools, and a great
urgency for effective therapies and biomarkers to predict more
accurately the response to a therapy in order to avoid unnecessary
drug administration and the accompanied side effects. This paper will
give a detailed and comprehensive overview of metabolomics:
metabolomics and its uses, relation to cancer, and the future of the
ﬁeld.
2. Metabolomics techniques
Metabolomics is a technique of analyzing the cellular metabolites
(~2000 metabolites) and most common techniques used for
proﬁling metabolites are NMR and MS. MS mostly requires
chromatographic separation before MS to increase resolution.
Commonly used chromatographic systems are high performanceechniques Ref.
1 NMR [14]
1 NMR [15]
as Chromatography-Mass Spectroscopy [99]
MR [100]
MR [16]
1 NMR [101]
as Chromatography-Mass Spectrometry [11]
ydrophilic interaction chromatography-mass spectrometry [13]
PLC [102]
MR [103]
as Chromatography/time-of-ﬂight mass spectrometry [10]
MR and GC-MS used for 13C-isotopomer-based metabolic analysis [23]
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MS) and gas chromatography (GC/MS). Table 3 compares both of
these techniques. Although GC-MS relies heavily on derivatization
chemistry it has been more commonly used because of high
resolution and sensitivity over NMR. LC-MS can overcome limita-
tions of derivatization chemistry in GC/MS and is well suited for
samples or metabolites that cannot bear volatile treatment condi-
tions of GC/MS. Recent technological advances has led to the
development of Fourier-transform-ion cyclotron resonance mass
spectrometry (FT-ICR) which allows direct infusion and has high
resolution [18,19].
To clearly associate the spectra to compounds, deconvolution of
NMR spectra is required and current technologies still suffer from
unclear signal discrimination. Ludwig et al. have developed a fast
targeted multidimensional Hadamard-encoded NMR spectroscopy
method that can not only deconvolute NMR spectra of blood
obtained from colorectal cancer patients but also have fast
acquisition property [20]. Wen et al. applied NMR-based metabo-
lomics on bile collected from individuals with biliary tract cancer or
benign biliary tract disease and included pattern recognition and
multivariate data analysis to achieve signiﬁcant differences between
cancer and benign individuals compared to other conventional
approaches [21].
LC/MS and GC/MS rely on chemometrics tool, data mining and
multivariate data analysis for classiﬁcation of metabolite peaks. Often,
these tools are built-in and programmed in the instrument. Recent
advances have led to the usage of nonlinear unsupervised classiﬁca-
tion techniques like Kohonen networks for structure identiﬁcation
and artiﬁcial neural networks for classiﬁcation of unknown spectra
against spectral libraries available from National Institute for
Standards and Technology (NIST).
The tracer techniques are useful for obtaining mechanistic
understanding of metabolic maps during disease progression,
malignant transformations, and epigenetic modiﬁcations leading
to altered metabolism. The isotopomer techniques work on the
principle of isotopic enrichment at different atomic positions in a
desired metabolic product, i.e. a labeled metabolite after undergoing
a metabolic reaction leads to an isotope-labeled product whose
enrichment allows uncovering of the source of alternate pathways
in generating that product. Using labeled isotopes, tracing can be
done back to the precursor molecules and thus reveal unique
distribution of ﬂuxes, information about ﬂux ratios, and direction-
ality of enzymatic reactions. Both NMR and MS are commonly used
for isotopomer analysis and resolution of metabolites occurs
because of shifts in frequency. However, FT-ICR is gaining
popularity because of its ultra high mass resolution and signiﬁcant
advantage over other MS techniques due to non-requirement of
prior chromatographic separation [18,19,22]. The advantage of
stable isotope labeled metabolomics approach in cancer is theTable 3
Comparison of various metabolomic techniques.
Characteristics NMR
Sensitivity Medium
Sample preparation Easy. Non-destructive sample preparation.
Limitations Not widely used in clinic, not high throughput
for analysis of metabolites, need special training
to use equipment
Reproducibility High
Resolution High
Quantiﬁcation Easy
Throughput Lowpresence of a large library of 13C-labeled isotopes, including 13C-
labeled glucose, 13C-labeled glutamine, serine, glycine, other amino
acids, 13C-labeled saturated fatty acids, and 13C-labeled acetate, thus
allowing determination of metabolic pathways in cancer related to
protein and fatty acid synthesis, nucleic acid synthesis, ribose
moieties of the nucleotides, citric acid cycle and glycolytic cleavage
of carbohydrates. Generally, in isotopomer techniques, both stable
and labile metabolites extraction techniques are similar to non-
isotope techniques; however, they both differ in terms of structure
elucidation techniques.
3. Metabolomics in cancer
A ﬂurry of recent work has established that metabolomics
approaches can serve as an important tool for detection, prognosis,
biomarker discovery and design of therapeutics. Metabolomics
involves collection of biological samples to be analyzed for metabolic
changes associated with certain disease conditions. Biological
samples commonly utilized include blood, urine, and tumor tissue.
Denkert et al. used gas chromatography/time of ﬂight mass
spectrometry (GC-TOF MS) to analyze ovarian cancer metabolism
in both invasive carcinomas and borderline tumors (noninvasive
and have proliferation rate similar to benign tumors) [10]. In their
study authors found 51 metabolites (out of a total of 291 different
metabolites) to be different between invasive carcinoma and
borderline tumors. They connected these metabolites using Kyoto
Encyclopedia of Genes and Genomes (KEGG) to different pathways
and enzymes and detected differences in glycerolipid (glycerolpho-
sphate alpha, inositol-phosphate and glucose-1-phosphate), free
fatty acid (nonadecanoic, stearic, heptadecanoic acid), amino acid
metabolism (proline, glutamic acid, glycine, γ-aminobutyric acid,
glutamine, threonine, and asparagine) and energy metabolism
(malic and fumaric acid). Interestingly, malignant tumors had
higher metabolic turnover rates, nitrogen donor amino acids
(glutamate, glutamine and asparagine), and amino acids serving as
building blocks in protein biosynthesis (cysteine, glycine and
threonine). Denkert et al. performed metabolite proﬁling of normal
and colon cancer tissue and found 82 metabolites out of 206 to be
signiﬁcantly different in two groups [8]. Metabolites involved in
citrate cycle were lower in cancer tissues compared to normal colon
samples. There was an upregulation of precursors needed for DNA
synthesis (purines) and amino acids (protein synthesis). Interest-
ingly, authors found that the most important metabolite for
alteration of metabolism in colon cancer is β-alanine, which
was highly upregulated in carcinoma tissues. Fan et al. infused 13C-
glucose into human lung cancer patients and analyzed resected
tissues and blood plasma by 13C-isotopmer-based metabolomic
studies using NMR and GC/MS. In their study, authors found that in
lung tumors there was increased incorporation of carbon fromMS Ref.
High
Medium—often need separation methods to increase
peak capacity and derivitization
[104,105]
High cost, not widely used in clinics, need special training
to use equipment
[104]
Low for bioﬂuids
High because of liquid chromatography or gas chromatography [67]
Difﬁcult [104]
High [18,19]
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moiety of nucleotides, and aspartate relative to noncancerous lung
tissue [23].
As mentioned earlier, Warburg effect indicates that cancer cells
have altered or dysfunctional mitochondrial metabolism. Metabo-
lomics is a promising technique to unravel differences in mitochon-
drial pathways between invasive carcinomas with border line
tumors and/or normal tissues. Hirayama et al. used capillary
electrophoresis time-of-ﬂight mass spectrometry for 16 colon and
12 stomach cancer patients and performed quantiﬁcation of 94
metabolites in colon and 95 metabolites in stomach involved in
glycolysis, the pentose phosphate pathway, the TCA and urea cycles,
and amino acid and nucleotide metabolisms [24]. Authors found
signiﬁcant organ level differences in TCA cycle metabolites indicat-
ing the dependence of tissue on oxygen and nutrition availability.
Most importantly, authors show in their work that metabolomics
could be efﬁciently used to understand altered energy metabolites in
cancer.
Below we will review the current and potential applications of
metabolomics using various bioﬂuids, its use in cancer diagnosis and
prognosis, and for studying bioenergetics of cancer.
3.1. Metabolomic proﬁling of urine
Urine is often collected and analyzed in order to identify cancer
biomarkers. The ability to analyze urine for biomarkers of disease is
advantageous when compared to many other screening techniques
since it is completely non-invasive and does not cause harm to
patients. It has been shown that analyzing urine of individuals with
breast cancer and screening for multiple biomarkers can have a
similar sensitivity to traditional mammography without exposing the
patient to x-rays [25]. Analyzing urine for biomarkers could also
provide a convenient way to screen individuals for cancer, especially
when cancer is difﬁcult to screen and detect, such as ovarian cancer
[26] and hepatocellular carcinoma [11].
Utilizing urine for metabolic screening and biomarker identiﬁ-
cation employs similar methods that are used for analyzing other
biological ﬂuids of cells. After urine is collected from both diseased
and healthy individuals, chromatography techniques, including gas
chromatography and liquid chromatography, followed by mass
spectrometry techniques are used in order to separate and identify
metabolites for both the diseased and normal cases. Analysis
techniques used to cluster or separate the diseased and normal
cases are employed to determine whether metabolites detected
can be used to discriminate normal individuals from diseased
patients.
Urine has been analyzed for biomarkers for various cancers,
including hepatocellular carcinoma [11], breast cancer [25], lung
cancer [27], and colorectal cancer [28]. Analysis of collected urine
has revealed metabolic changes that can be potentially used to
discriminate between cancer patients and non-diseased individ-
uals. Since RNA metabolism is altered in cancer, it was hypothe-
sized by Hsu et al. that metabolomic studies on colorectal cancer
patient urine using high performance liquid chromatography,
liquid chromatography, and mass spectrometry can show that
nucleosides are altered in cancer compared to normal cases. The
group showed that higher amounts of 5 different nucleosides were
present in urine from colorectal cancer patients in comparison to
normal individuals [29]. Urine has also been shown to distinguish
patients with lung cancer from normal patients, as opposed to
breath tests that are more difﬁcult to perform than urine collection
and have low speciﬁcity. More speciﬁcally, volatile components
were shown to be of lower levels in cancer patients as opposed to
normal individuals, which is speculated to be linked to metabolic
changes associated with cancer [28]. In a study conducted by Woo
et al., urine was collected and analyzed for biomarkers of threewomen's cancers: breast, ovarian, and cervical cancer. Using both
LC/MS and GC/MS, the group found potential biomarkers for each
cancer, some in relation to oxidative DNA damage, a possible
contributor to cancer development [26]. In addition to cancer
biomarker discovery, urine analysis has been used to determine
biomarkers for highly aggressive forms of cancer as opposed to
less aggressive forms. For example, increased levels of sarcosine, an
N-methyl derivative of glycine, were shown to be associated with
more aggressive and invasive forms of prostate cancer through
urine metabolomics [30]. Studies that link a biomarker with a stage
and aggressiveness of disease are important since it can potentially
increase the likelihood of giving a patient the appropriate therapy,
thus reducing that patient's side effects and increasing one's
quality of life.
Although the use of urine in metabolomics has led to the
identiﬁcation of potentially useful biomarkers for cancer, it still faces
numerous challenges, among which the key hurdles are: (i) some
metabolites are non-volatile in urine and need to be derivatized
before injection when using gas chromatography [11]; (ii) it is also
difﬁcult to determine whether samples were collected after a
speciﬁed period of time, and proper procedures must be adopted
while performing the analysis to compensate for this uncertainty
[29]. As with other biological samples, care must be taken when
handling and preserving urine specimens to avoid variable results.
Urine, for example, cannot be thawed and refrozen many times,
which can change the composition, and thus affect the results of the
experiment [31]. Lastly, urine composition tends to vary with diet
more than with other biological ﬂuids and thus could increase
variability in metabolomic proﬁling [32]. Despite these complicating
factors, urine collection and analysis still provides a convenient
way to study cancer metabolism and detect cancer biomarkers
[13,30,33].
3.2. Metabolomic proﬁling of blood/serum
DeSilva et al. applied NMR spectroscopy for metabolic footprint-
ing of lipid metabolites in human serum using 31P containing
derivatization reagent 2-chloro-4,4,5,5-tetramethyldioxaphospho-
lane (CTMDP) and obtained high sensitivity and spectral resolution
for lipophilic components [34]. Their approach holds promise
because it is highly quantitative and thus will aid in analyzing
lipodsytrophies in human serum. In an interesting study, Hartmann
et al. (2008) performed metabolic proﬁling of colon cancer cells
using solid phase microextraction (SPME) followed by GC/MS and
found that type and amount of serum supplementation plays
a major role in inducing metabolic differences in these groups
[35,36].
3.3. Metabolomics proﬁling of saliva
Although saliva is an important bioﬂuid, it has not been widely
used for studying cancer diagnosis. Recently, Sugimoto et al. [37]
performed metabolic footprinting of saliva from patients with
oral, breast and pancreatic cancer using capillary electrophoresis
mass spectrometry, and the study revealed signiﬁcant differences
between pancreatic cancer patients and healthy controls in eight
metabolites (leucine, isolecuine, tryptophan, valine, glutamic acid,
phenylalanine, glutamine, and aspartic acid) and taurine and piperidine
in oral cancers.
3.4. Clinical factors
3.4.1. Prognosis
Metabolomics guided prognosis holds promise for cancer
prognosis and is gaining hold in cancer recurrence, metastatic
potential, and post surgery analysis. Metabolomics based methods
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surgery clinical or pathological criteria may not hold well. In
prostate cancer, although the patients' prognosis is done based on
the serum PSA levels before surgery, after prostectomy, extracap-
sular extensions, lymph node metastasis are combined to predict
recurrence after prostatectomy. Furthermore, after surgery the
information obtained from examination of prostate is currently the
only viable way to know about malignancy. Maxeiner et al. used ex
vivo tissue magnetic-resonance-spectroscopy based metabolomics
proﬁles to investigate the recurrence of prostate cancer and using
principal component analysis predicted the recurrence with 78%
accuracy [38]. Denkert et al. [10] found that differences in metabolic
proﬁles in invasive and borderline ovarian tumors were linked to
prognostic factors such as dihydropyrimidine dehydrogenase and
thymidine phosphorylase [39]. Sitter et al. used ERETIC (Electronic
reference To access in vivo concentrations) an advanced technique
for quantifying metabolites in breast cancer patients using high
resolution magic angle spinning MR spectroscopy (HR MAS MRS)
with different prognosis [40]. Interestingly, authors found lower
concentrations of glycine in patients with good prognosis and higher
concentrations in patients with poor prognosis. In metastatic
patients or patients who had recurrence, the authors found lower
values of taurine/glycine and GPC/glycine compared to patients who
were healthy 5 years after surgery. Their results show that these
metabolite ratios can play an important role in prognosis and
recurrence.
3.4.2. Diagnosis
Many cancers go undetected or patients present themselves at
late stage when cancer has already metastasized and surgery
remains the only intervention. Moreover, surgery may not often
lead to cure because of either cancer recurrence after surgery or due
to multi-organ syndrome. Hence, development of early detection
strategies is key to success in developing medical treatment in
cancer. Sreekumar et al. used metabolomic proﬁles obtained by
highly sensitive and speciﬁc isotope dilution GC/MS to distinguish
benign prostate, clinically localized prostate cancer and metastatic
disease [30]. Their results showed that level of sarcosine, an N-
methyl derivative of the amino acid glycine, was increased during
prostate cancer progression and was highly upregulated in invasive
prostate cancer cell lines (VCaP, DU145, 22RV1) relative to benign
prostate epithelial cells (PrEC) and immortalized benign RWPE
prostate cells. The comparative metabolomics analysis between
benign and clinically localized prostate cancer revealed differential
expression in 87 out of 518 metabolites, 50 of which were
upregulated and 37 of which were found to be downregulated.
Additionally, when metastatic samples were compared to clinically
localized prostate cancer samples, 124 out of 518 metabolites were
found to increase in metastatic samples and 102 metabolites were
downregulated. In general, sarcosine, kynurenine, glycerol-3-phos-
phate, leucine and proline were signiﬁcantly increased in prostate
cancer. They concluded that sarcosine levels correlated well with cell
invasiveness and the exogenous addition of sarcosine and its
precursor glycine transformed the phenotype of benign prostate
epithelial cells into a more invasive one. To further test the
speciﬁcity of sarcosine with respect to invasiveness, knockdown of
sarcosine dehydrogenase—the enzyme that degrades sarcosine—was
done. The authors found that invasive phenotype in benign cells
increased in the knockdown cells. Interestingly, master transcrip-
tional regulator of prostate cancer, androgen receptor along with the
ETS gene fusions was found to transcriptionally regulate sarcosine
levels. Urayama et al. used mass spectrometry based metabolite
proﬁling to develop biomarkers for detecting pancreatic cancer from
blood plasma and suggest that plasma concentration of lipids, amino
and bile acids may play an important role in early detection of
pancreatic ductal adenocarcinoma (PDAC) [36].3.5. Metabolomics of mitochondrial disorders in cancer-perspective
applications
Altered mitochondrial electron transport systems and respiratory
chain disorders have been known to induce signiﬁcant changes in
metabolic pathways in cancer. However, metabolomics has still not
found foothold to study these aberrant changes in cancer. High
prevalence of mitochondrial disorders in cancer and unavailability of
current approaches in providing genome scale or systems biology
based understanding of mitochondrial dysfunction demands novel
tools to study metabolic alterations induced by these disorders.
Recent applications of metabolomics to study mitochondrial disor-
ders indicate that it could potentially serve as a promising tool to
investigate the link between cancer and mitochondrial disorders.
Shaham et al. metabolically proﬁled the cultured media of a
respiratory chain disease (RCD) induced in differentiated muscle
cells using inhibitors of enzymatic complex I (rotenone) and
complex III (antimycin) embedded in the inner mitochondrial
membrane using targeted mass spectrometry [41]. The authors
found that cultures treated with respiratory chain (RC) inhibitors
had higher glucose uptake, lactate and alanine secretion, and lower
biogenesis of proteins and phospholipids. Further, they combined
the cellular model with clinical investigation involving patients
having either pathogenic mutations or an abnormally low respira-
tory chain enzyme activity in muscle. Interestingly, metabolite
proﬁling of plasma obtained from RCD patients (16 patients with 25
healthy controls) revealed the similar pattern and both lactate and
alanine levels were elevated. Moreover, in plasma, they found
creatine and uridine levels to be altered in similar way as in cell
culture.
A recent study using mitochondrial metabolomics has linked long
chain fatty acid oxidation with metabolite signatures of TCA cycle
intermediates in skeletal muscle [42]. The authors used GC-TOF/MS to
identify intra- and extra-mitochondrial metabolites and pathway
ﬂuxes and associated palmitate oxidation ﬂuxes with mitochondrial
metabolites. Interestingly, Mervaala et al. used tissue-based metabo-
lomics using GCxGC-TOF/MS to understand angiotensin-induced
mitochondrial dysfunction and usage of cardiac substrate [43].
Angiotensin contributes greatly to stroke, congestive heart failure in
patients with hypertension-induced ventricular hypertrophy, and
using metabolic proﬁle data authors linked angiotensin-induced
changes to alterations in mitochondrial biogenesis, respiratory chain
enzyme activities, and suggested upregulation of SIRT1 to counteract
mitochondrial dysfunction. In an effort to pin down the role of fatty
acids in mitochondrial dysfunction in skeletal muscle insulin
resistance, Koves et al. used targeted metabolomics and showed
that a high fat diet results in excessive β-oxidation [44]. This is in
contrast with current theory that muscle insulin resistance is due to
impaired mitochondrial uptake and oxidation fatty acids and thus
changes the paradigm of the need to upregulate β-oxidation during
insulin resistance.
Genomic mutations are known to initiate cancer. The application
of metabolomics to study metabolic alterations during DNA damage
and link them with tumorigenesis could provide fundamental
understanding of neoplasia and cancer progression. In a recent
study, a novel application of metabolomics was presented to screen
mice for the desired diseased phenotype after mutagenesis. Authors
used tandem MS/MS to screen mice with defect in mitochondrial
trifunctional protein (MTP) complex that catalyzes β-oxidation of
long chain fatty acids. Metabolomics generated mouse models will
allow development of treatment strategies for humanmitochondrial
disorders. The same group earlier used a similar approach to
develop mice for abnormalities in mitochondrial-branched chain
aminotransferase deﬁciency resembling human maple syrup disease
[45]. This approach could be easily extended to study cancer
metabolism.
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Most of the current metabolomics approaches provide useful information about the metabolic proﬁles and are a good aid in cancer and disease
diagnostic studies. However, they are restricted inproviding onlymetabolic pattern information and thus a staticmetabolicmap. Themetabolic pathway
ormetabolicnetwork-basedapproaches commonlyused for analyzingmicrobialmetabolismarenowgaining recognition inmammalianstudies, andare
versatile enough to capture not only dynamic metabolite perturbations due to environment, diet, and epigenetic changes but also can provide
information about source of the speciﬁc alterations inmetabolism or dysregulatedmetabolism [46–49]. Either themetabolic pathway approaches could
be used as a standalone metabolite proﬁling technique or the information obtained could be integrated with the existing metabolomics data. The
pathway-based approaches are based on topological and stoichiometric construction of the metabolic map and further determination of metabolic
ﬂuxes. The enzyme-mediated reactions are ﬁrst collected from annotated genome and then later stoichiometric information is added for active enzyme
using biochemistry data and certain imposed assumptions based on the knowledge of certainty of reaction directions. The next step involves estimation
of intracellularﬂuxesusingmetabolicﬂux analysis (MFA) framework,which relies on steady-state assumptions, stoichiometric andpathway constraints
of a metabolic pathway network, and on constrained nonlinear optimization technique. MFA has been used extensively for studying themetabolism of
microorganisms [50–54], and has been recently applied to compare different physiological states in mammalian systems [55–63].
Hiller et al. [64] have recently developed a nontargeted tracer fate detection technique using stable isotope tracers for quantitative detection of
labeledmetabolites andpathways involved in themetabolismofused tracer. In their approach, authors used lungcarcinomacell line to obtain relative
ﬂux magnitudes of each metabolite pool and found increased ﬂux through glutaminolysis pathway using [U-13C5] labeled glutamine. Interestingly,
authors found increased branched chain amino (BCA) acid ﬂux for cells labeled with [a-15N] glutamine, which is remarkable because these amino
acids cannot be produced by the body and implications of them in cancer suggests involvement of other essential amino acids inmeeting the cellular
demandof nitrogen. Theﬁndings of the authors are signiﬁcant because theirmethodology is nontargeted, requires noa prioriknowledge ofmetabolic
pathway and metabolites, and allows for obtaining information of all labeled metabolites beforehand and identiﬁcation of perturbed metabolome.
Alternatively, stable isotope labeling based tracermethods can be integratedwithmetabolic footprinting framework andused for quantifying in vivo
ﬂuxes validation of the intracellular and extracellular MFA obtained ﬂuxes [47,65–68]. In order to obtain a unique solution for the intracellular ﬂux
distribution in a cell or tissue system, a minimum number of measurements of rates of uptake and release of extracellular metabolites by the system is
required. However, if there are insufﬁcient ﬂuxmeasurements available, then pathway ﬂuxes are predicted using constrained optimization techniques
[49,69–72]. However, optimization problem formulation in mammalian systems needs to take into account several cellular objectives. This is based on
the hypothesis that mammalian cells at any time, whether they are in diseased or healthy state, need to maintain homeostasis of several different
metabolites. Thus, homeostasis conditions, thermodynamic constraints, physical constraints, stoichiometric constraints, are incorporated as equality and
inequality constraints along with the inferred cellular objectives in an optimization problem to solve for intermediary metabolism and intracellular
ﬂuxes. It is to be noted that inferring cellular objectives is a complex problemand in diseases such as cancer andmetabolic diseases such as diabetesmayFig. 2.Metabolic ﬂux analysis based pathway tracing of cancer. MFA approaches can serve as validation andmechanistic tool. This can be done using either isotopomer-based in vivo
ﬂux analysis or using metabolomic footprinting approaches. For determination of intracellular and pathway ﬂuxes measured ﬂuxes are combined with physical and thermodynamic
constraints and solved using nonlinear multiobjective optimization methods that take into account cellular objectives.
657D. Nagrath et al. / Biochimica et Biophysica Acta 1807 (2011) 650–663need an iterative or a multilevel optimization approach [73–76]. Cancer cells typically not only undergo cell proliferation, but also perform an array of
metabolic functions (protein secretion, detoxiﬁcation, energy production and lipid synthesis), and therefore different andmultiple objectives need to be
taken into account. Their interaction with stroma, their altered mitochondrial metabolism, and maintenance of nutrition supply makes them possess
multiple functions including efﬁcient uptake and subsequent metabolic conversion of amino acids, carbohydrates, lipids, and vitamins. Subsequently,
these nutrients are either stored or released after biochemical transformations. These biochemical processes make the tumor microenvironment the
epicenter of the metabolic modulation of intermediary metabolism and thus plays an important role in therapeutic strategies targeting tumor
metabolism. Several techniques have been developed for analyzing multiple cellular objectives including Bayesian and optimization-based approaches
[60,72,77,78]. Recently we have developed a combined energy and ﬂux balance based large-scale nonlinear multiobjective framework for mammalian
systems, which can be easily integrated with cancer metabolomics. Our multiobjective optimization based ﬂux balance analysis approach, LPPFBA
(Linear Physical Programming-Based Flux Balance Analysis), employs Linear Physical Programming (LPP), and enables the formulation of the
optimization problem in terms of physicallymeaningful terms and parameters, by employing “soft constraints.” Fig. 2 shows the detailed framework for
estimation of intracellular pathway ﬂuxes.
4.1. Metabolic ﬂux analysis
The stoichiometric coefﬁcients of the metabolic reactions are collected into a stoichiometric matrix S, where each element sij is the coefﬁcient
of metabolite i in reaction j. S has dimensions ofM×N, whereM is the number of metabolites andN is the number of reactions. Inmatrix form, the
mass balance is written as:
dx
dt
= SJ ð1Þ
where each element xi of x is the intracellular concentration of metabolite i and element Ji of J is the net rate of conversion in reaction j. External
metabolite ﬂuxes are generallymeasured (e.g., uptake/secretion of glucose, pyruvate, lactate, amino acids, and fatty acids). The very high turnover of
the intracellular pools of most intracellular metabolites allows the pseudo steady state assumption to the metabolite mass balances and thus
SJ = 0 ð2Þ
In most of the humanmetabolome systems, quantitative measurement of all the metabolites is challenging and in reality the number of measured
quantities is always less than the number of measurements required for the system to be determined (which is approximately close to the number of
metabolic reactions in metabolic pathways). Hence, the computation of unknown intracellular ﬂuxes in human metabolome will require linear
optimization (since inﬁnite number of solutions can exist) with linear bound constraints. Mathematically, this is be expressed as:
max
Ju
cT Ju ð3Þ
subject to
Su Ju = −Sm Jm ð4Þ
Jlow≤ Ju≤ Jhigh ð5Þ
where the vector c speciﬁes unknown ﬂux vector elements to be maximized (or minimized); vectors Jlow and Jhigh provide the lower and upper
bounds for the unknown ﬂuxes; Jm and Ju indicate measured and unmeasured ﬂuxes, respectively; and Sm and Su contain the stoichiometric
coefﬁcients of measured and unknown reactions, respectively.
4.2. Multiobjective optimal metabolic ﬂuxes
A multiobjective optimization is a problem involving several competing objectives and constraints. A Pareto optimal solution is one where any
improvement in one objective can only take place at the cost of another objective. A Pareto set is a set of Pareto-optimal solutions. Often several Pareto
optimal points are available in cellularmetabolic systems, representing alternativeobjectives scenario, fromwhich cells select theone that offers the best
trade-off amongmultiple objectives basedonstill unknowncriteria. This optimizationgenerally involves forminganAggregateObjective Function (AOF)
(or, some functional aggregation of themany conﬂicting criteria). Implicit in this process is the assumption that this AOFhas the ability to indeedyield all
the potentially useful/desirable optimal solutions. The most common AOF structure is the weighted-sum approach, which involves forming a linear
combination of objectives-minimized subject to the problem constraints. We have recently developed Linear Physical Programming (LPP) based
multiobjective FBA inwhichweexpress thepreferencesof cellular objectivesusingdifferent classes [49]. Each class comprises twocases, softandhardand
all soft class functions are integrated in the AOF (that is minimized). Constraints that have to be met are classiﬁed as hard. All the soft class functions
become part of the AOF to be minimized, and all of the hard class functions simply appear as constraints in the LPP model.
Thedesiredbehaviorof anobjective function, duringoptimization, isdescribedby sub-classes, soft (S) andhard (H). These classes aredeﬁnedas follows:
Soft
Class-1S Smaller-Is-Better, i.e. minimization
Class-2S Larger-Is-Better, i.e. maximization
Class-3S Range-Is-Better
Class-IVS Value-Is-BetterHardClass-1H Must be smaller, i.e., gi≤ ti,max
Class-2H Must be larger, i.e., gi≥ ti,min
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subclasses. For anexample, ifweknowapriori fromexperimental data or literature that cells of a certain diseasewill be eitherminimizing aparticular
cellular function, then we will choose Class-1S and assign ﬁve desirability preference values for this function (highly desirable, desirable, tolerable,
undesirable, and highly undesirable). These preference values are used to form an aggregate objective function, which is then used to compute
unknown intracellularmetabolicﬂuxes. Fig. 3 shows the target valueswhich are assigned in LPP for Class-IVproblemwhere the desiredobjective is to
maintain homeostasis of the cellular function. For Class-IV cellular objective, wewould assign desired preferences or targets in terms of their desired
andundesired ranges (highly undesirable, desirable, tolerable, undesirable andhighly undesirable). The proposed LPP approach is advantageous over
currently used techniques for optimization and estimation of these unknown ﬂuxes because LPP requires target values which are in physical units of
cellular functions, whereas commonly used techniques require meaningless weights which do not have physical meanings and may not provide
correct estimation of intracellular ﬂuxes for large-scale networks such as cellular networks.
4.2.1. Constrained multiobjective metabolic ﬂux analysis framework
The following linear programming problem is then solved:
Piecewise Archimedean aggregate function:
zi = min
d−is ; d
þ
is
∑
5
s=2
w˜−is d
−
is + w˜
þ
isd
þ
is
 
ð6Þ
subject to System constraints:
Su Ju = −Sm Jm ð7Þ
Jlow≤Ju≤Jhigh ð8Þ
x min≤x≤x max ð9Þ
Goal Constraints:
gi−d
þ
is≤t
þ
i s−1ð Þ; d
þ
is≥0; gi≤t
þ
i5 s = 2;…;5ð Þ ð10Þ
gi + d
−
is ≥t
−
i s−1ð Þ;d
−
is ≥0; gi≥t
−
i5 s = 2;…;5ð Þ ð11Þ
gj≤tj; max for all j in class 1H; j = 1;2…nhcð Þ ð12Þ
gj≥tj; min for all j in class 2H; j = 1;2…nhcð Þ ð13Þ
gj = tj;val for all j in class 3H; j = 1;2…nhcð Þ ð14Þ
tj; min≤gj≤tj; max for all j in class 4H; j = 1;2…nhcð Þ ð15ÞFig. 3. Description of Linear Physical Programming. LPP approach involves assigning preferences or desirability and undesirability ranges instead of meaningless weights for the cellular
objectives. These targets for ranges are used in optimization during metabolic ﬂux analysis to estimate unknown intracellular metabolic ﬂuxes. In most of the genome-scale metabolic
networks, optimization is necessary to estimate unknownﬂuxes. This is because stoichiometricmap is hard tobe fully determinedusing experimentalmeasurements. Hence, optimization
is used to determine these unknown intracellular ﬂuxes. Current techniques estimate these ﬂuxes using weights of cellular objectives (for example, maximization of ATP, redox balance,
nucleotide production). However, LPP assigns targets to these objectives and hence avoid ill-conditioning and accurately estimates unknown metabolic ﬂuxes [49].
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As discussed previously, the use of preferences for different degrees of desirability aids in simultaneous visualization of a large number of
objectives. This facilitates the assessment of the effect of preference speciﬁcations on the objectives as well as the complex interplay of these
objectives. Each section is color coded according to the desirability level and labeled.
4.2.2. Metabolic thermodynamic constraints
Energy Balance Analysis (EBA) developed to ensure the thermodynamic feasibility of the computed ﬂuxes imposes the thermodynamic
constraints onmetabolic reaction ﬂuxes [76,79–82]. Essentially, EBA integration inMFA involves the computation of the reaction potentials based
on the chemical potentials. Further, thermodynamic constraints based on the ﬁrst and second laws of thermodynamics are obtained by reaction
potentials, and these constraints further reduce the feasible solution space based on stoichiometric constraints. It is important to note that
environmental constraints such as cell culture conditions, medium supplements, oxidative stress and extracellular matrices, typically limit the
feasible solution space even further. For any reaction set, if stoichiometry is represented by matrix S, μ denotes an M-dimensional vector of
chemical potentials, Δμ denotes the N-dimensional vector of reaction potentials, then these potentials can be computed as Δμ=STμ. The ﬁrst law
of thermodynamics necessitates energy conservation, which then leads to an equality constraint as
KTΔμ = KTSTμ = 0 First Law of Thermodynamics Based Energy Equality Constraintð Þ ð16Þ
The second law of thermodynamics takes the form of an inequality constraint for each ﬂux as− JiΔμi≥0. The vector of net ﬂux distribution
through the reaction network can be then computed as J= J+−J−, which then leads directly to the second law of thermodynamics, i.e.,
−JjΔμ j = −RT Jjþ−J
j
−
 
ln
J j−
J jþ
 !
≥0 Second Law of Thermodynamics Based Energy In Equality Constraintð Þ ð17Þ
which says that the systemmust dissipate heat, and entropymust increase as a result of thework being done on the system through the external ﬂuxes.
The other inequality constraint is by ensuring that the total heat dissipation rate of the living system is always positive as indicated by
hdr = −JTΔμ N 0 Inequality Heat Dissipation Constraintð Þ ð18Þ
Since hdr→0 in the limit as J− / J+→1 component-wise while maintaining J= J+−J− so to prevent this physically unrealistic possibility, an
additional inequality constraint
hdrð Þlb≤hdr≤ hdrð Þub Inequality Heat Dissipation Constraintð Þ ð19Þ
is also imposed as part of Energy Balance Analysis. The procedure for estimation of intracellular ﬂuxes using thermodynamic constraints is
illustrated below for a toy problem of two cycle metabolic network.
4.2.3. Two-cycle metabolic network
The steady state mass balances for metabolites A, B, C and D in terms of reaction ﬂuxes are given by the following equations used in this
metabolic network (Fig. 4):
d A½ 
dt
= JA−J1−J3 = 0
d B½ 
dt
= J1 + J2−J5−JB = 0
d C½ 
dt
= J3−J2−J4−JC = 0
d D½ 
dt
= J4 + J5−JD = 0Fig. 4. Two cycle and four node metabolic network.
660 D. Nagrath et al. / Biochimica et Biophysica Acta 1807 (2011) 650–663where the internalﬂuxes for J1, J2 and J3 are J1=k1[A]−k−1[B], J2=k2[C]−k−2[B] and J3=k3[A]−k−3[C], and J4=k4[C]−k−4[D] and J5=k5[B]−
k−5[D]. Above equations can be cast into a stoichiometric matrix form as:
Aeq =
− k1 + k3ð Þ k−1 k−3 0 1 0 0 0
k1 − k−1 + k−2 + k5ð Þ k2 k−5 0 −1 0 0
k3 k−2 − k−3 + k2 + k4ð Þ k−4 0 0 −1 0
0 k5 k4 − k−4 + k−5ð Þ 0 0 0 −1
2
664
3
775
and x→= A½  B½  C½  D½  JA JB JC JD T
h
and beq = 0 0 0 0½ T . The chemical potential associated to reactions 1, 2 and 3 are given by
equations
Δμ1 = RTln
B½ 
K1 A½ 
 
Δμ2 = RTln
B½ 
K2 C½ 
 
Δμ3 = RTln
C½ 
K3 A½ 
 
For Reactions (4) and (5), it can be expressed as follows:
Δμ4 = RTln
D½ 
K4 C½ 
 
and
Δμ5 = RTln
D½ 
K5 B½ 
 
In order to have null chemical potential of the cycles, these relationships must satisfy: Δμ1−Δμ2−Δμ3=0 and Δμ4−Δμ2−Δμ5=0. These
equations are equivalent to K1=K2K3 and K4=K2K5. For this metabolic network, the cellular objective could be maximization of a cellular
function JI. The unknown intracellular ﬂuxes are estimated by maximizing cellular objectives as follows:
Maximize
x→
JIð Þ
subject to: Aeq x
→= b
→
eq
HDRlb≤HDR≤HDRub
x→lb≤ x
→≤ x→ub
4.3. Metabolic ﬂux analysis and bioenergetics of cancer metabolism
The preceding methodology of metabolic ﬂux analysis (MFA) can be utilized to estimate the unknown intracellular ﬂuxes in the cancer
metabolic network. The advantage of using multiobjective metabolic ﬂux analysis is that it easily allows incorporation of cellular objectives
in tumorigenesis, such as maximization of glycolysis (Warburg effect) and minimization of mitochondrial TCA cycle ﬂuxes in a
straightforward manner. Additionally, metabolic ﬂuxes of mitochondrial and glycolytic pathways in cancer can reveal metabolic pathways
upregulated and downregulated in cancer. Notably, the stoichiometric analysis can be combined with GC-HPLC-MS and/or NMR techniques
to conﬁrm the increase and decrease of metabolic cycle ﬂux and thus can be used to integrate qualitative data (presence or absence of
metabolic ﬂuxes) with quantitative metabolic ﬂuxes. Using separate compartments for mitochondrial and cytoplasmic metabolites, MFA can
reveal altered pathway ﬂuxes linked to mitochondrial biogenesis, respiratory chain enzyme activities and uptake and oxidation of fatty acids
during tumor progression and growth [49,72]. The development of metabolic network analysis map for diseases such as cancer could reveal
the dysregulated complex cancer pathways and metabolic interaction networks that regulate the disorders in mitochondrial metabolism.
Using novel systems tools such as optimality and thermodynamics based metabolic network we could obtain nutrition based therapies for
regulating cancer metabolism at all levels of complexity and thus modulate carcinogenesis.
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Bain et al. describe various advantages of metabolomics over other
“omics” technologies in diabetes research: (a) it requires signiﬁcantly
less small molecule metabolites; (b) it provides a measure of
integrated phenotypic changes in genome, transcriptome and
proteome [83]. In the aim toward developing targeted strategies for
pancreatic islet cell transplantation NMR-based mass isotopomer
techniques have been utilized for studying glucose metabolism in
insulin secreting cells and determining mitochondrial pathways that
are responsible in generating coupling factors using glucose respon-
siveness and unresponsive [84]. In these approaches, cells are cultured
with [U-13C] glucose followed by NMR-based isotopomer analysis of
secreted glutamate. This allows the determination of glucose to
pyruvate and its entry into TCA cycle through catalytic conversion by
pyruvate dehydrogenase (PDH) into acetyl COA. Alternatively,
pyruvate can enter TCA cycle through catalytic conversion by
pyruvate carboxylase (PC) which converts it into oxaloacetate. The
isotopomer peak analysis allows analysis of the relative rates of each
ﬂux by observing the secreted cycle components. Recently, non-
targetedmetabonomic proﬁling of plasma and urine using UPLC-qTOF
mass spectrometry revealed metabolic ﬁngerprinting differences
occurring in normal glucose tolerant and impaired glucose tolerant
(IGT) individuals affected by the pre-diabetic metabolic state [85]. In
their study, major metabolic alterations were found in fatty acid,
tryptophan, uric acid, bile acid, and lysophosphatidylcholine, as well
as the TCA cycle metabolites. In a similar study [86], using a
combination of 1H nuclear magnetic resonance spectroscopy and
liquid chromatography-tandemmass spectrometry, insulin deﬁciency
induced altered metabolic pathways were determined in plasma
obtained from type 1 diabetic humans during insulin treatment and
acute insulin deprivation and non-diabetic participants. The meta-
bolic ﬁngerprinting revealed in type 1 diabetes perturbations of
pathways involved in protein synthesis and breakdown, gluconeo-
genesis, ketogenesis, amino acid oxidation, mitochondrial bioener-
getics, and oxidative stress; and elevation of lactate, acetate, allantoin,
ketones during insulin deprivation. In an interesting study, Zyromski
et al. [87] analyzed pancreatic fat content in fatty pancreas and
compared various conventional approaches such as thin-layer and gas
chromatography with NMR-based metabolomics. Their results corre-
lated well with conventional approaches in the quantiﬁcation of fat,
triglycerides and phospholipids.
Recently ﬁndings began to elucidate the role of metabolomics for
biomarker discovery in arthritis as well [5,88]. Zhai et al. analyzed
serum samples of 123 osteoarthritis cases and 299 healthy controls
using targeted metabolite ﬁngerprinting by electrospray ionization
tandemmass spectrometry and found ratios of valine to histidine and
leucine to histidine correlated with osteoarthritis [88]. The study
conﬁrms that the usage of metabolite concentrations instead of
enzymatic reaction rates could serve as a biomarker and sets the stage
for using this concept in a clinical setting. In another study [5], using
1H NMR spectroscopy based metabolomics approach, authors found
that uracil, xanthine, and glycine are the likely biomarkers of a
systemic inﬂammatory joint disease rheumatoid arthritis.
Although in infancy, another area where metabolomics has sparked
a strong interest is the area of reproductive biology that involves
assessment of oocyte quality by metabolic phenotyping of follicular ﬂuid
in order to identify the most viable embryo that will result in pregnancy
[89–91].
6. Future directions
Metabolomics although is at its infancy could serve as a key tool in
cancer and disease diagnosis. Further developments in the area of
advanced metabolite detection technologies and data analysis will
provide impetus for wide usage in clinical medicine. However, thereare some challenges that need to overcome before recent metabo-
lomics studies can lead to the development of “cancer metabolome”
and biomarkers derived from metabolite proﬁling approaches could
facilitate personalized therapy. On metabolomics technological front,
to harness the power of various metabolomic techniques it will be
necessary to use both NMR andMS based approaches. This will widen
the range of analytes and compounds that could be detected for
comprehensive metabolomics studies. Current metabolomics tech-
nology faces tough uphill battles in developing structural identiﬁca-
tion databases, spectral libraries of vast compounds. The combination
of chemometrics approaches such as multivariate data analysis,
principle component analysis with systems biology approaches such
as nonlinear multiobjective optimization and time-series models
developed for many years in adaptive control community can provide
a structural identiﬁcation of analytes from complex spectra.
Studying metabolic proﬁling of bioﬂuids is critical not only from
biomarker perspective but also because the integration of metabolic
markers for cancer phenotype obtained from tissue, cells and bioﬂuids
may elucidate the novel role of metabolic markers and could provide
better understanding of metabolic adaptations and alterations
because of diet and environment. Furthermore, a combined approach
involving metabolomics of various bioﬂuids may allow development
of metabolic markers necessary to understand resistant forms of
cancer in the era of personalized medicine.
There is a pressing need to further investigate metabolomics
application in clinical cancer research using in vivometabolomics such
as PET imaging and 13C-glucose infusion into human cancer patients.
This will demonstrate predictive value of metabolomics derived
biomarkers and enable study of drug resistances and cancer
recurrence. Notably, chemotherapy and radiation induced cell death
is another important area where metabolite proﬁling could assist in
identifying dysfunctional pathways during drugs induced apoptosis.
In future, metabolic and nutrition based approaches could address
induced and altered metabolic changes by diet and metabolic
activators.
Lastly, it will be important to validate metabolomics data using
ﬂuxomics and metabolic ﬂux analysis approaches. The integration of
pathway-based dynamic metabolic proﬁling approaches that are based
on topological and stoichiometric construction of the metabolic map
with static metabolome may provide much needed mechanistic
understanding of cancer metastasis and malignant transformations
during tumor growth. Moreover, these approaches could allow
inference of cellular and tissue metabolic objectives, and contribute to
identiﬁcation ofmetabolic factors that trigger the onset of cancer. Given
that cancer cells and its interaction with tumor microenvironment is
quite complex, complete understanding of biochemical pathways in
cancer necessitates the use of multiobjective optimization approach to
determine metabolic ﬂuxes and/or infer cellular objectives in cancer.
Together, studies in metabolomics and ﬂuxomics could reveal the
complex cancer pathway and interaction network that regulates the
dysregulation of metabolism and aid in development of new person-
alized cancer therapies, cancer diagnosis, prognosis, and early detection.Acknowledgments
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